Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,365Revenue $M119Net Margin (%)-194.6Altman Z-Score-3.2
Enterprise Value $M1,566EPS $-1.2Operating Margin %-182.9Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.4Pre-tax Margin (%)-197.4Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio2.1Cash flow > EarningsY
Price/Sales11.45-y EBITDA Growth Rate %--Current Ratio2.1Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-40.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M190ROIC % (ttm)-231.2Gross Margin Increase y-yY

Gurus Latest Trades with ARIA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARIAMichael Price 2015-12-31 Add0.08%$5.78 - $7.19
($6.57)
$ 7.189%Add 14.45%820,000
ARIAMichael Price 2015-09-30 Add0.15%$5.81 - $9.89
($7.71)
$ 7.18-7%Add 30.27%716,500
ARIAJoel Greenblatt 2015-06-30 Sold Out $7.9 - $9.71
($8.83)
$ 7.18-19%Sold Out0
ARIAMichael Price 2015-03-31 Buy 0.6%$6.1 - $8.97
($7.39)
$ 7.18-3%New holding550,000
ARIAJoel Greenblatt 2015-03-31 Buy $6.1 - $8.97
($7.39)
$ 7.18-3%New holding16,344
ARIAGeorge Soros 2014-12-31 Sold Out -0.01%$5.02 - $7.46
($6.28)
$ 7.1814%Sold Out0
ARIAGeorge Soros 2014-09-30 Reduce-0.04%$5.01 - $6.5
($5.84)
$ 7.1823%Reduce -85.00%150,000
ARIAGeorge Soros 2014-06-30 Add0.02%$6.3 - $8.52
($6.89)
$ 7.184%Add 100.00%1,000,000
ARIAGeorge Soros 2014-03-31 Reduce-0.08%$6.46 - $8.99
($7.75)
$ 7.18-7%Reduce -74.36%500,000
ARIAGeorge Soros 2013-12-31 Buy 0.11%$2.2 - $18.8
($5.16)
$ 7.1839%New holding1,950,000
ARIAGeorge Soros 2012-06-30 Sold Out -0.15%$14.6 - $17.82
($16.35)
$ 7.18-56%Sold Out0
ARIAGeorge Soros 2012-03-31 Buy 0.15%$12.73 - $16.32
($13.74)
$ 7.18-48%New holding635,000
ARIAGeorge Soros 2011-12-31 Sold Out -0.07%$8.03 - $12.5
($10.96)
$ 7.18-34%Sold Out0
ARIAGeorge Soros 2011-09-30 Buy 0.07%$7.63 - $13.34
($10.54)
$ 7.18-32%New holding496,847
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARIA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARIA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-04-22Sell21,409$7.37-2.85view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-03-22Sell23,834$6.588.81view
BERSTEIN DAVID LSVP, Chief IP Counsel 2016-03-21Sell2,375$6.4710.66view
Bollag Daniel MSr. VP, Reg. Affairs & Quality 2016-03-21Sell4,000$6.4710.66view
FITZGERALD EDWARD MExecutive VP 2016-03-21Sell5,417$6.4710.66view
Haluska FrankSVP, Clinical R&D, CMO 2016-03-21Sell3,575$6.4710.66view
Duvall Martin JEVP, CCO 2016-03-19Sell4,000$6.4710.66view
Cantor Maria ESVP, Corporate Affairs 2016-03-19Sell3,575$6.4610.84view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-03-19Sell5,417$6.4710.66view
FITZGERALD EDWARD MExecutive VP, CFO 2016-03-03Sell9,625$6.1216.99view

Quarterly/Annual Reports about ARIA:

News about ARIA:

Articles On GuruFocus.com
Michael Price Invests in 11 Companies in First Quarter May 19 2015 
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 10 2009 
Weekly CEO Buys Highlight: Citigroup Inc, ARIAD Pharmaceuticals Inc, Bruker BioSciences Corp, Akamai Aug 08 2009 

More From Other Websites
ARIAD to Webcast Conference Call on First Quarter 2016 Financial Results Apr 26 2016
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events Apr 25 2016
ARIAD Announces Results of Preclinical Studies on AP32788 at the Annual Meeting of the American... Apr 19 2016
ARIAD Gains on Updated Brigatinib Phase I/II Study Data Apr 18 2016
ARIAD Presents Updated Phase 1/2 Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell... Apr 15 2016
Why one trader is selling Ariad calls Apr 12 2016
ARIAD Announces Initiation of Randomized, First-Line Phase 3 Trial of Brigatinib in Treatment of... Apr 11 2016
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Mar 29 2016
ARIAD Announces Reduction in Workforce as Part of Ongoing Company-Wide Strategic Review Mar 29 2016
WSJ story features local cancer drug as a success when used off-label Mar 29 2016
Five Cheap Healthcare Stocks With Hedge Fund Support Mar 24 2016
Are These Biotech Stocks Worth your Attention? CELG, ARIA, EXEL, and CMRX Mar 22 2016
Is Ariad Pharmaceuticals (ARIA) Stock a Solid Choice Right Now? Mar 22 2016
ARIAD Reports Inducement Grant to New Chief Financial Officer Mar 22 2016
Ubben Sells More Shares of Motorola Solutions Inc. (MSI), Meister Cuts Stake in This REIT, Plus 2... Mar 21 2016
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Mar 18 2016
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other... Mar 14 2016
Ariad replaces longtime CFO, hires second C-level officer this year Mar 11 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)